Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Überhitzung bremst Aufstieg: Palantir-Aktie stürzt ab – Fünf Tage in Folge im Minus nach... (Wallstreet-Online) +++ PALANTIR Aktie -3,06%

BAUSCH HEALTH Aktie

 >BAUSCH HEALTH Aktienkurs 
6.75 EUR    (Tradegate)
Ask: 7 EUR / 630 Stück
Bid: 6.5 EUR / 1179 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 8 bis 22 Uhr!
BAUSCHHEALTH Aktie über LYNX handeln
>BAUSCH HEALTH Performance
1 Woche: +11,5%
1 Monat: +21,8%
3 Monate: +61,1%
6 Monate: +7,7%
1 Jahr: +30,3%
laufendes Jahr: -8,4%
>BAUSCH HEALTH Aktie
Name:  BAUSCH HEALTH COS.
Land:  Kanada
Sektor:  Gesundheit
ISIN/ Wkn:  CA0717341071 / A2JQ1X
Symbol/ Ticker:  BVF (Frankfurt) / BHC (NYSE)
Kürzel:  FRA:BVF, ETR:BVF, BVF:GR, NYSE:BHC
Index:  TSXComp
Webseite:  https://www.bauschhealth...
Profil:  Bausch Health Companies Inc. is a diversified heal..
>Volltext..
Marktkapitalisierung:  2539.08 Mio. EUR
Unternehmenswert:  20303.28 Mio. EUR
Umsatz:  8646.57 Mio. EUR
EBITDA:  2736.19 Mio. EUR
Nettogewinn:  85.38 Mio. EUR
Gewinn je Aktie:  0.23 EUR
Schulden:  18659.51 Mio. EUR
Liquide Mittel:  1496.16 Mio. EUR
Operativer Cashflow:  1281.65 Mio. EUR
Bargeldquote:  0.35
Umsatzwachstum:  0.72%
Gewinnwachstum:  -
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Div. Historie:  10.11.10 - 0.9222€
Insiderhandel:  1 Insider kaufte innerhalb der letzten 30 Tage Aktien im Wert von 333.757.793 USD.
Suchwörter:  BAUSCH HEALTH, BAUSCHHEALTH
Letzte Datenerhebung:  20.08.25
>BAUSCHHEALTH Kennzahlen
Aktien/ Unternehmen:
Aktien: 369.79 Mio. St.
Frei handelbar: 78.96%
Rückkaufquote: -
Mitarbeiter: 20700
Umsatz/Mitarb.: 0.38 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: -13.01%
Bewertung:
KGV: 30.91
KGV lG: 2.14
KUV: 0.3
KBV: -
PEG-Ratio: -
EV/EBITDA: 7.42
Rentabilität:
Bruttomarge: 60.08%
Gewinnmarge: 0.99%
Operative Marge: 19.05%
Managementeffizenz:
Gesamtkaprendite: 0.37%
Eigenkaprendite: -
>BAUSCHHEALTH Peer Group

Es sind 185 Aktien bekannt.
 
18.08.25 - 23:06
Bausch + Lomb Announces Board Changes (Business Wire)
 
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the Amended and Restated Director Appointment and Nomination Agreement, dated as of June 21, 2022, by and among the company and Mr. Carl C. Icahn and certain of his affiliates, terminated pursuant to its terms when the Icahn group's net long position in the common shares of Bausch + Lomb's parent company, Bausch Health Companies Inc., fell below the required threshold. In connection with the termination, Brett M. Icahn and Gary Hu have resigned from the Bausch + Lomb Board of Directors. “I appreciate Brett and Gary's valuable contributions to the company over the past three years, and wish them well going forward,” said Brent Saunders, chairman and CEO, Bausch + Lomb. About Bausch + Lomb Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from bir...
15.08.25 - 20:42
Bausch Health Companies Inc.: Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes (Accesswire)
 
LAVAL, QC / ACCESS Newswire / August 15, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") today announced that Paulson Capital Inc. and certain affiliates ......
15.08.25 - 17:12
Bausch Health rises after $300M worth insider purchase (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
15.08.25 - 07:01
Insiderhandel: Aufsichtsrat kauft Aktien von Bausch Health Companies im Wert von 312490062 USD (Insiderkauf)
 
Paulson, John - Aufsichtsrat - Tag der Transaktion: 2025-08-14...
14.08.25 - 05:01
Insiderhandel: Aufsichtsrat kauft Aktien von Bausch Health Companies im Wert von 7957683 USD (Insiderkauf)
 
Paulson, John - Aufsichtsrat - Tag der Transaktion: 2025-08-12...
14.08.25 - 05:01
Insiderhandel: Aufsichtsrat kauft Aktien von Bausch Health Companies im Wert von 12700000 USD (Insiderkauf)
 
Paulson, John - Aufsichtsrat - Tag der Transaktion: 2025-08-11...
14.08.25 - 05:01
Insiderhandel: Aufsichtsrat kauft Aktien von Bausch Health Companies im Wert von 610048 USD (Insiderkauf)
 
Paulson, John - Aufsichtsrat - Tag der Transaktion: 2025-08-13...
12.08.25 - 22:33
DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health (PR Newswire)
 
Bausch Health will pay $1.75 per share plus up to $350 million in aggregate sales milestones Transaction expected to close in the third quarter of 2025 CUPERTINO, Calif., Aug. 12, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the second......
07.08.25 - 14:07
Bausch Health Companies Inc.: Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners (Accesswire)
 
For the Sixth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 Scholarship LAVAL, QC / ACCESS Newswire / August 7, 2025 / Bausch Health Companies Inc. (NYSE:B......
31.07.25 - 18:15
Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat (Zacks)
 
BHC stock falls 6.3% as Q2 earnings miss estimates despite stronger sales and growth in key segments like Salix and Solta Medical....
31.07.25 - 05:39
Bausch Health reaffirms 2025 revenue target of $4.95B–$5.1B as debt reduction and pipeline expansion advance (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
31.07.25 - 04:00
Bausch Health (BHC) Lags Q2 Earnings Estimates (Zacks)
 
Bausch (BHC) delivered earnings and revenue surprises of -7.22% and +2.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...
30.07.25 - 22:18
Bausch Health Companies Inc.: Bausch Health Announces Second Quarter 2025 Results (Accesswire)
 
Second Quarter Consolidated Revenues of $2.53 billion, up 5% on a Reported basis and 4% on an Organic (non-GAAP)1 basis over the prior year periodGAAP Net Income Attributable to Bausch Health Compa......
29.07.25 - 20:48
Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout (Benzinga)
 
Bausch Health will acquire DURECT and larsucosterol, aiming for FDA approval of a first treatment for alcoholic hepatitis via Phase 3 trials. read more...
29.07.25 - 14:42
Bausch Health to acquire liver drug developer Durect for $1.75 per share (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
29.07.25 - 13:54
Bausch Health To Acquire DURECT; Expanding Liver Disease Pipeline With Larsucosterol (AFX)
 
OTTAWA (dpa-AFX) - Bausch Health Companies Inc. (BHC), a pharmaceutical company, on Tuesday announced that it has signed a definitive agreement to acquire DURECT Corp. (DRRX), gaining access to it......
28.07.25 - 15:54
Bausch Health to redeem ~$602M of outstanding notes due 2026 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
28.07.25 - 15:18
Bausch Health Companies Inc.: Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand (Accesswire)
 
LAVAL, QC / ACCESS Newswire / July 28, 2025 / Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company") today announced that its subsidiary, Bausch Health Americas, Inc.......
24.07.25 - 14:18
Bausch Health Companies Inc.: Bausch Health Announces the Appointment of Two New Members to Its Board of Directors (Accesswire)
 
LAVAL, QC / ACCESS Newswire / July 24, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced the appointment of Michael Goettler and......
18.07.25 - 03:36
Best Stock to Buy Right Now: Bausch Health vs Canopy Growth? (Fool)
 
While both stocks are risky, Bausch Health is seeing operational momentum, while Canopy Growth is still struggling with losses. The post Best Stock to Buy Right Now: Bausch Health vs Canopy Growth? appeared first on The Motley Fool Canada....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Am Anfang war die Kraft. - Paula Modersohn-Becker
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!